Methyl B12 – 15 mg
Superior form of B12 to prevent deficiency
- High dose vitamin B12 in its most effective form
- Promotes healthy nerve function
- Helps prevent pernicious anemia
- Delivered in a pleasant tasting lozenge for enhanced absorption
$57.44 — or subscribe and save 20%
Methyl B12 provides a high dose of the active, coenzyme form of vitamin B12. Cyanocobalamin, the most common form of supplemental B12, must be converted first into hydroxocobalamin, and then into adenosylcobalamin, which is finally converted into methylcobalamin. Taking methylcobalamin directly allows you to bypass this extensive conversion process, and is optimal since it is the specific form of B12 shown to support the brain and nervous system. In humans, supplementation with high doses of methylcobalamin has been shown to provide neurological support in people with degenerative nerve conditions such as Bell’s palsy, multiple sclerosis, Lou Gehrig’s disease and degenerative spinal conditions. Methylcobalamin may also help normalize sleep-wake cycles, providing a better quality sleep for those who are deficient.
AOR’s Methyl B12 provides 15 mg in an easy to take, pleasant-tasting lozenge. This ultra-high dose formula has been shown to be safe and effective for people with advanced neurological conditions such as ALS or MS. Additionally, vegetarians, elderly people, those suffering from pernicious or megaloblastic anemia, atrophic gastritis, Celiac disease, Crohn’s disease or other types of inflammatory gastrointestinal disorders may benefit from high doses of methylcobalamin.
While the RDA (Recommended Dietary Allowance) for vitamin B12 in Canada is just 2.4 micrograms and the upper limit is just 1 milligram, AOR’s Methyl B12 – 15mg provides an ultra-high, clinically effective dosage of the most bioavailable form of vitamin B12 in a convenient and pleasant tasting lozenge form.
Methyl B12 – 15 mg is an ultra-high-dose formulation of methylcobalamin, a source of vitamin B12 that helps prevent vitamin B12 deficiency. This higher-potency formulation of AOR’s Methyl B12 supplement is for individuals for whom research supports higher levels of supplementation.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Dissolve one lozenge under the tongue first thing in the morning and repeat one to three times a day with/without food, or as directed by a qualified health care practitioner.
Consult a health care practitioner if you are pregnant or breastfeeding or for use beyond four months.
- Promotes healthy nerve function
- Lozenges sweetened with xylitol
- Contains a form of B12 superior to cyanocobalamin
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: Microcrystalline cellulose, sodium stearyl fumarate, xylitol, tapioca syrup, distilled water and hydroxypropyl cellulose.
Nerve Health and Cognition
Methylcobalamin in Autism Spectrum Disorder (ASD)
This 2016 randomized placebo-controlled trial examined the effects of methylcobalamin in the management of autism spectrum disorder symptoms. This eight-week study subjects with methyl B12 subcutaneously injected (75mcg/kg) or saline every three days. B12 status as well as the following assessment tools: CGI- improvement (a physician assessment tool), aberrant behaviours checklist (ABC), and social function measured by the Social Responsiveness scale (SRS.) The baseline ASD severity was comparable among the placebo and treatment groups. At the end of eight weeks, researchers found that the treatment group had a statistically significant improvement in CGI scores from 2.4 vs placebo at 3.1, and 52% of children in the treatment group were deemed responders (reporting “much improved” or “very much improved”). Secondary outcomes of the motivation subscale of the SRS and the irritability subscale of the ABC showed improvement in the treatment group over the placebo.
Hendren RL, James SJ, Widjaja F, Lawton B, Rosenblatt A, Bent S. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism. J Child Adolesc Psychopharmacol. 2016;26(9):774-783. doi:10.1089/cap.2015.0159 https://pubmed.ncbi.nlm.nih.gov/26889605/
Neuropathies-Post Thoracotomy Pain
This 2016 pain examined the impact of combined therapy of pregabalin and methylcobalamin on post-thoracotomy pain. This common condition following intense operations is associated in large part to neuropathic pain. One hundred patients recovering from thoracometies with at least three months of chronic pain were enrolled. A visual analogue scale and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale were used to evaluate the pain severity and type. The participants completed 3 months of treatment. The treatment group was given PG-B12 dosages were as follows: 300 mg/day PG and 1 mg/day B12 for the first seven days, then 600 mg/day PG, and 1 mg B12 until the 90th day. While the comparison group continued with the conventional treatment of DP 50 mg three times for the first seven days and then, on-demand, as was required by the patient. Researchers found that VAS scores at day 15 and LANSS scores at day 30 were significantly lower in the PG-B12 group than in the DP group. Indicating improved combined therapy for the management of neuropathic pain.
Metin SK, Meydan B, Evman S, Dogruyol T, Baysungur V. The Effect of Pregabalin and Methylcobalamin Combination on the Chronic Postthoracotomy Pain Syndrome. Ann Thorac Surg. 2017;103(4):1109-1113. doi:10.1016/j.athoracsur.2016.09.031 https://pubmed.ncbi.nlm.nih.gov/27916242/
Use in ALS
In this multicentre, randomized, double-blind, placebo-controlled clinical trial published in 2019- 373 patients with ALS into placebo ( n=124), 25 mg methylcobalamin ( n=124) or 50 mg methylcobalamin (n=125) group-administered intramuscularly twice per week for 12 weeks initially and then an additional 182 weeks. The primary endpoint was the ALSFRS-R score and any of the following events: death by any cause or invasive or non-invasive ventilation support ≥22 hours per day due to ALS progression. Secondary endpoints included: muscle strength assessed using the manual muscle test, physical functional status measured with the Norris Scale, respiratory function assessed using %FVC, grip strength, and the quality of life evaluated using the ALS Assessment Questionnaire-40. Assessments were conducted on week 0, 4 and 16, and at 12-week intervals thereafter to week 172, and on week 182. While the primary endpoint results did not vary significantly the treatment groups showed a longer time to primary event meaning that the treatment may have delayed progression of the ALS particularly in patients in early stages of disease progression.
Kaji R, Imai T, Iwasaki Y, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomized controlled study. J Neurol Neurosurg Psychiatry. 2019;90(4):451-457. doi:10.1136/jnnp-2018-319294 https://pubmed.ncbi.nlm.nih.gov/30636701/
Prevention of B12 Deficiency
Oral Methylcobalamin at 15 mg per Day for High-risk Group with Gastrectomy
This 2011 single-arm open-label fixed drug dosage trial assessed the impact of oral methylcobalamin supplementation on the safety and efficacy of oral supplementation in patients with total gastrectomy (i.e., no intrinsic factor-dependent b12 absorption with an anticipated deficiency). The treatment group (n=30) received three 500 mcg tablets of methylcobalamin for a total of 1500 mcg daily. A second study was also conducted for intramuscular vitamin B12 replacement using cyanocobalamin (1000 mcg weekly for five weeks and monthly thereafter). The results found oral replacement therapy provides safe and effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients and that they do not have to get intramuscular injections. Further, the oral methylcobalamin group had fewer neurological symptoms of tingling.
Kim HI, Hyung WJ, Song KJ, Choi SH, Kim CB, Noh SH. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Ann Surg Oncol. 2011;18(13):3711-3717. doi:10.1245/s10434-011-1764-6 https://pubmed.ncbi.nlm.nih.gov/21556950/